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Abstract
Background: Single Nucleotide Polymorphisms (SNPs) identified in Genome Wide Association Studies (GWAS) have
generally moderate association with related complex diseases. Accordingly, Multilocus Genetic Risk Scores (MGRSs)
have been computed in previous studies in order to assess the cumulative association of multiple SNPs. When several
SNPs have to be genotyped for each patient, using successive uniplex pyrosequencing reactions increases analytical
reagent expenses and Turnaround Time (TAT). While a set of several pyrosequencing primers could theoretically be
used to analyze multiplex amplicons, this would generate overlapping primer-specific pyro-signals that are visually
uninterpretable.
Methods: In the current study, two multiplex assays were developed consisting of a quadruplex (n=4) and a
quintuplex (n=5) polymerase chain reaction (PCR) each followed by multiplex pyrosequencing analysis. The aim was
to reliably but rapidly genotype a set of prostate cancer-related SNPs (n=9). The nucleotide dispensation order was
selected using SENATOR software. Multiplex pyro-signals were analyzed using the new AdvISER-MH-PYRO software
based on a sparse representation of the signal. Using uniplex assays as gold standard, the concordance between
multiplex and uniplex assays was assessed on DNA extracted from patient blood samples (n = 10).
Results: All genotypes (n=90) generated with the quadruplex and the quintuplex pyroquencing assays were
perfectly (100%) concordant with uniplex pyrosequencing. Using multiplex genotyping approach for analyzing a set
of 90 patients allowed reducing TAT by approximately 75% (i.e., from 2025 to 470 min) while reducing reagent
consumption and cost by approximately 70% (i.e., from∼ 229 US$ /patient to∼ 64 US$ /patient).
Conclusions: This combination of quadruplex and quintuplex pyrosequencing and PCR assays enabled to reduce
the amount of DNA required for multi-SNP analysis, and to lower the global TAT and costs of SNP genotyping while
providing results as reliable as uniplex analysis. Using this combined multiplex approach also substantially reduced
the production of waste material. These genotyping assays appear therefore to be biologically, economically and
ecologically highly relevant, being worth to be integrated in genetic-based predictive strategies for better selecting
patients at risk for prostate cancer. In addition, the same approach could now equally be transposed to other
clinical/research applications relying on the computation of MGRS based on multi-SNP genotyping.
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Background
Since 2005, a large number of Genome-Wide Associa-
tion Studies (GWAS) have identified Single Nucleotide
Polymorphisms (SNPs) associated with more than 300
complex diseases and traits [1]. For prostate cancer (PCa),
47 risk-associated SNPs have been identified [2] that are
essentially found in 8q24 and 17q chromosomal regions
although not strictly restricted to these areas. Most of
these SNPs have been tested in large population surveys
as stand-alone predictors.
Considering that each SNP has only a moderate
association with PCa, Multilocus Genetic Risk Scores
(MGRSs) were computed in different studies to assess
the cumulative association of multiple SNPs. Zheng
et al. assessed the cumulative effect of five selected
SNPs [3]. Compared to men without any of these risk
genotypes, the odds ratio for PCa was 4.47 (2.93-6.80)
in those having four of them or more. Kader et al.
computed MGRS based on 33 established PCa risk-
associated SNPs and demonstrated the potential added
value of the score for PCa risk prediction [4]. More
recently, a MGRS computed from a set of nine published
SNPs (rs1016343, rs16901979, rs6983267, rs4242382,
rs10993994, rs10896449, rs4430796, rs1859962, and
rs5945619) improved the performance of a clinical
risk-calculator in predicting prostate biopsy result [5].
The predictive performance of the integrated clinico-
genetic model (AUC = 0.781) was higher than the
predictive performance of the clinical score alone
(AUC = 0.770). This set of nine risk-associated SNPs
was selected from the breast and prostate cancer cohort
consortium (BPC3) results [6], according to reported
allelic odds ratio, prevalence and potential linkage
disequilibrium.
While approaches for identifying men at high risk
of PCa are still needed, the costs of genetic testing
are currently too high to perform large-scale screen-
ing [7]. Consolidating a broader use of genetic test-
ing in PCa early detection algorithms will require a
cheaper and faster though equally high throughput and
reliable procedure. Pyrosequencing is a cost-effective
DNA sequencing technique that has many applications,
including rapid SNP genotyping. The chemilumines-
cent signal produced during the reaction is detected
in the pyrosequencer and displayed in a pyro-signal
(i.e., a pyrogram™) which is then translated into the
corresponding nucleotide sequence. Usually, genotyping
a single SNP is carried out with one separate reaction
in one well (i.e., a uniplex experiment). Genotyping of
multiple SNPs using uniplex pyrosequencing requires
therefore performing multiple simultaneous or succes-
sive reactions for each patient, which impacts reagent
costs and Turnaround Time (TAT). A more efficient alter-
native would be to use simultaneously a set of several
pyrosequencing primers in a single well (i.e., a multiplex
reaction).
Duplex (n=2) and triplex (n=3) pyrosequencing applica-
tions for SNP genotyping were recently developed using
LBP [8], CTLA-4 [9], or CYP2C19 [10] target genes. In
these applications, nucleotide dispensation orders were
carefully selected and successfully avoided overlapping
primer-specific signals. However, only one gene with two
to three different SNPs were assayed. For some multiplex
pyrosequencing applications, overlapping primer-specific
signals are unavoidably created and visually uninter-
pretable. Accordingly, the AdvISER-M-PYRO software
was recently and specifically developed to allow the anal-
ysis of overlapping pyro-signals generated from multi-
plex reactions (i.e, the comprehensive set of each peak
height characterizing a well-defined pyro-sequence in
uniplex experiments or a combination thereof in multi-
plex experiments) [11, 12]. In parallel, the pyrosequencing
nucleotide dispensation order was improved by devel-
oping the SENATOR (“SElecting the Nucleotide dispen-
sATion Order”) algorithm. AdvISER-M-PYRO is based
on the modelling of multiplex pyro-signals as a sparse
representation of elements (named atoms) from a stan-
dardized learning dictionary that includes corresponding
uniplex pyro-signals. The first application of SENA-
TOR and AdvISER-M-PYRO consisted in genotyping
alterations underlying bacterial resistance to β-lactam
antibiotics [12].
In the present study, two multiplex assays were devel-
oped consisting of a quadruplex and a quintuplex PCR,
each followed by pyrosequencing analysis for genotyping a
set of PCa-related SNPs (n=9) [5]. The dispensation order
was selected using SENATOR and multiplex pyro-signals
were analyzed with an adapted version of AdvISER-M-
PYRO (named AdvISER-MH-PYRO), which integrates a
new function allowing bi-allelic SNP genotyping. The
analytical reagent costs, waste production and TAT of
conventional uniplex and new multiplex pyrosequencing
assays were compared.
Methods
Patients and DNA extraction
Both multiplex pyrosequencing assays were developed
and validated on DNA extracted from patient blood
(n = 10). These patients had been included in a previ-
ous study [5] and provided informed consent, following
approval of the study by the Ethics Committee (Comité
d’Ethique Hospitalo-Facultaire, Cliniques Universitaires
Saint-Luc - Université Catholique de Louvain, Brussels).
The extraction of genomic DNA was performed
from peripheral blood lymphocytes using the EZ1
DNA Blood kit and BioRobot EZ1 (Qiagen, Leusden,
The Netherlands), according to the manufacturer’s
protocol.
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Selection of the pyrosequencing dispensation order
A list of all unique nucleotide sequence (UNS) expected
to be found in the 9 selected genomic regions was com-
piled (Table 1). Considering that pyrosequencing experi-
ments were designed with reverse primers for some SNPs
(Tables 1 and 2), the complementary sense sequence
was computed for the corresponding UNS. Allocation of
each of the nine SNPs either to quadruplex or quintu-
plex assay was made according to optimal PCR conditions
commonly used for individual SNP genotyping. Then, the
SENATOR [12] function was used to generate a suitable
nucleotide dispensation order for both quadruplex and
the quintuplex assays.
Uniplex andmultiplex PCR and pyrosequencing
Identification of the nine SNPs was first carried out for
all patients (n=10) using uniplex (n=9) PCRs, followed
by uniplex pyrosequencing reactions (n=9). All genotypes
(n=90) resulting from uniplex pyro-signals were used as
gold standard.
In the following steps, quadruplex PCR followed by
quadruplex pyrosequencing was carried out on four SNPs,
while quintuplex PCR followed by quintuplex pyrose-
quencing was carried out on the remaining five SNPs
(Table 1). Although protocols for individual SNP geno-
typing differed initially in terms of MgCl2 concentration
(2.25 or 3.0 mM) and number of PCR cycles (35 or 40),
subsequent condition testing allowed to standardize the
PCR multiplex protocol.
Multiplex PCR was carried out in a 50 μL reaction
mixture containing 7 or 10 μL (for quadruplex and
quintuplex assays, respectively) of the extracted DNA
(50 ng), 5 μL of a PCR buffer (100 mM Tris hydrochlo-
ride, and 500 mM potassium chloride, pH 8.3), 3mM
MgCl2, 1U AmpliTaq Gold® DNA Polymerase (Ampli-
Taq Gold® DNA Polymerase kit from Applied Biosys-
tems®, Austin, USA), 200μM of each deoxynucleotide
triphosphate (dNTPs: dATP, dCTP, dGTP, dTTP Li-salts
from Roche Diagnostics GmbH, Mannheim, Germany)
and forward and reverse PCR primers (Table 1) (Euro-
gentec, Liège, Belgium). Amplification was performed
in a 2720 Thermal Cycler (Applied Biosystems®) using
the following conditions: 95 °C for 5 minutes, followed
by 40 cycles with denaturation at 95 °C for 40 seconds,
annealing at 60 °C for 40 seconds, and extension at 72 °C
for 80 seconds, with a final extension step at 72 °C for
7 minutes. Electrophoresis of PCR products was per-
formed on 2% agarosis gel. Pyrosequencing was then
carried out with a pyrosequencer PyroMark PSQ 96 MA
Sequencer from Qiagen (Hilden, Germany) on PCR prod-
ucts, using a mixture of the pyrosequencing primers
(0.4μMeach) (Table 2), enzymes and substrate (PyroMark
Gold® Q96 Reagents kit, Qiagen) according to the
manufacturer’s protocol. Each PCR and pyrosequencing
Table 1 List of selected SNPs (n=9) and their corresponding MAF, OR and UNS
SNP Chromosome Allelic MAFa Unique Nucleotide Forward Quadruplex(n=4)
ORa Sequences (UNS) Reverse Quintuplex (n=5)
rs1016343 8 1.25 0.21 TTCCCTCCCA Reverse 4
TTCCCTCTCA
rs10993994 10 1.23 0.47 TGACGTCGAA Forward 4
TGATGTCGAA
rs16901979 8 1.44 0.18 ATCTGGCAAA Forward 4
CTCTGGCAAA
rs5945619 X 1.23 0.26 ACTCCCGCCG Reverse 4
ACTCCCGCTG
rs10896449 11 0.84 0.4 GCTGAAAATT Reverse 5
GCTGAAAGTT
rs1859962 17 1.19 0.39 TGATGAACAC Forward 5
GGATGAACAC
rs4242382 8 1.4 0.16 CCACAGGCCC Forward 5
CCGCAGGCCC
rs4430796 17 0.8 0.46 GATGCTGCAT Forward 5
AATGCTGCAT
rs6983267 8 0.81 0.43 TGAAAGGCAC Reverse 5
TGAAAGTCAC














Table 2 PCR and pyrosequencing primers and primer concentrations for each selected SNP before and after concentration adjustment
SNP Quadruplex (n=4) Multiplex PCR Multiplex PYRO
Quintuplex (n=5) Conc.(μM)
Primer Initiala Adjusteda Primer Conc.(μM)
rs1016343 4 F: 5’-Biot-TCAGGGCAATTACGGAATAACA-3’ 0.1 0.1 5’-TGAAGCTGTGAGTAATCA-3’ 0.4
R: 5’-AATCTAAAGAATGGGGGTCAGAG-3’ 0.1 0.1
rs10993994 4 F: 5’-CTCTCCTCCTCTGCTCTTTTAGGT-3’ 0.1 0.1 5’-TTGTTATCATTCCCAA-3’ 0.4
R: 5’- Biot- AGGCAAAGCTGCATCAAACT-3’ 0.1 0.1
rs16901979 4 F: 5’-GTGGGGTCTTTGTTGTGGA-3’ 0.1 0.1 5’-AATGATTTAGCATTACTTAT-3’ 0.4
R: 5’-Biot-TTATGTTCAGAGCGGTTGAATG-3’ 0.1 0.1
rs5945619 4 F: 5’-Biot-CAGGAAGGGGAACATCACACT-3’ 0.1 0.05 5’-CTTGCGGGAGTCTCA-3’ 0.4
R: 5’- ACGGCTACTATGAGATGAGGAAAC-3’ 0.1 0.05
rs10896449 5 F: 5’-Biot-GGGCCACAGGGAACAA-3’ 0.1 0.15 5’-TGACATTCCCCTTCTTA-3’ 0.4
R: 5’-GCCTTTTCAATGAACCCACA-3’ 0.1 0.15
rs1859962 5 F: 5’-AATAAGAGGCTGCAGACTTTTCC-3’ 0.1 0.05 5’-AAATCCCTGCCCGTG-3’ 0.4
R: 5’-Biot-TAGGCATTCCAAAGATGAAGACTC-3’ 0.1 0.05
rs4242382 5 F: 5’-AAAAGAGGTAACCCAGGGAACA-3’ 0.1 0.075 5’-TTGTCCCTCTAGTTATCTTC-3’ 0.4
R: 5’-Biot-GCATAGAGGGACGCTGTCAA-3’ 0.1 0.075
rs4430796 5 F: 5’-ACGTCCCTTCCTCAGCATCTT-3’ 0.1 0.3 5’-GGCAGCACAGACTGGA-3’ 0.4
R: 5’-Biot-TGTTCCTGACATGAAGCAACTCT-3’ 0.1 0.3
rs6983267 5 F: 5’-Biot-TCTTCCTATCTCAGCTCCCTATCC-3’ 0.1 0.1 5’-AATTCTTTGTACTTTTCTCA-3’ 0.4
R: 5’-GTTGGCTGGCACTGTCTGT-3’ 0.1 0.1
aFor each SNP, the concentrations of PCR primers were adjusted in order to select the best conditions for balancing the respective contribution of each SNP in multiplex pyro-signals
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reaction included a negative control. All uniplex and mul-
tiplex pyrosequencing reactions were carried out with the
selected dispensation orders. They were also compared
in terms of analytical reagent costs, production of waste
material and TAT.
Multiplex pyro-signal processing using AdvISER-MH-PYRO
All multiplex pyro-signals were converted into their corre-
sponding genotypes in three successive steps, as described
below. Firstly, two standardized learning dictionaries were
created, one for the quadruplex, the other for the quin-
tuplex assay. Each dictionary includes a uniplex theoret-
ical pyro-signal for each genotype expected to be found
within each genomic region. Aside of the theoretical
uniplex pyro-signals (i.e., 7 and 10 in the quadruplex
and quintuplex assay, respectively), those generated by
uniplex pyrosequencing were also included in both dic-
tionaries. These experimental uniplex pyro-signals were
standardized by dividing all peak heights by the corre-
sponding first unitary peak height (FUPH), as previously
recommended [12].
In a second step, each multiplex pyro-signal was ana-
lyzed with AdvISER-MH-PYRO software. While not
included with the previous AdvISER-M-PYRO version
which was dedicated to bacterial DNA genotyping, a
new feature was implemented into AdvISER-MH-PYRO
in order to carry out bi-allelic SNP genotyping. For
these SNPs, the pyro-signal generated by a heterozy-
gous variant results from the superposition of pyro-
signals generated by both corresponding homozygous
allelic variants which, as expected, disclose peak heights
twice higher than their heterozygous counterparts (Fig. 1).
When the contribution of each homozygous and het-
erozygous variant is computed for a bi-allelic SNP,
a correction factor is then applied by the AdvISER-
MH-PYRO version, taking this effect into account.
AdvISER-MH-PYRO was implemented in an R package
(www.uclouvain.be/ctma.html) that can be applied to ana-
lyzemultiplex signals generated in a broad range of human
SNP genotyping applications.
In a final step, the optimal primer concentration was
adjusted for each SNP of both multiplex assays. Accord-
ingly, multiplex PCR and pyrosequencing reactions were
first carried out with an initial PCR primer concentra-
tion (0.1 μM for each SNP) on a first subset of patients
(n=3), and contributions of each SNP to the global mul-
tiplex pyro-signal were computed with AdvISER-MH-
PYRO. Concentrations of PCR primers were then adjusted
in order to select the best conditions for balancing the
respective contribution of each SNP in multiplex pyro-
signals (Table 2).
Interoperability of the dictionary
Considering that the multiplex pyrosequencing approach,
as described in this study, requires building a standardized
dictionary based on experimental uniplex pyro-signals,
an essential feature of the method appears therefore the
interoperability of this dictionary for analyzing multi-
plex pyro-signals generated by different pyrosequencers.
Accordingly, multiplex (quadruplex and quintuplex) pyro-
signals generated with the PyroMark Q96 ID sequencer,
Qiagen (Hilden, Germany), were analyzed using the same
dictionary and AdviSER-PYRO software and compared to
original results generated by PyroMark Q96MA.
Results and discussion
Selection of the nucleotide dispensation order
SENATOR was used to select a dispensation allow-
ing to differentiate between all UNSs of interest for
the current application (Table 1). Nucleotide dispen-
sation orders with 14 (CTGCATGACTCGAT) and
15 (AGATCGCTACGACTG) nucleotides were selected
rs1016343.CC
C T G C A T G A C T C G A T
rs1016343.TT
C T G C A T G A C T C G A T
rs1016343.CT
C T G C A T G A C T C G A T
Fig. 1 pyro-signals generated by each rs1016343 homozygous (CC and TT) and heterozygous (CT) variants
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for the quadruplex and quintuplex assays, respec-
tively. They generated theoretical uniplex pyro-signals
with low pairwise correlation coefficients, avoiding
collinearity between signals which are contained in
the dictionary and used as predictors in the penal-
ized regression models within the AdvISER-MH-PYRO
function.
For both multiplex assays, the theoretical multiplex
signals corresponding to all possible combinations of
genotypes were generated. The maximum values of the
pairwise correlation coefficients between all multiplex
signals were equal to 0.9891 and 0.9892 for the quadru-
plex and quintuplex assays, respectively. Therefore, the
selected dispensation orders proved to generate a spe-
cific and unique multiplex pyro-signal for each genotypic
combination.
Uniplex pyrosequencing
Uniplex pyro-signals of all DNA samples (n=10) were
obtained with the nucleotide dispensation order corre-
sponding to the quadruplex or quintuplex SNP allocation,
and used as gold standard genotype (Table 3).
Adjustment of PCR primer concentration
Regarding the quadruplex pyro-signals before primer
adjustment, the average relative signal contribution of
rs5945619 was higher (35.3%) than the three other SNPs
(15.9%, 27.4% and 21.4% for rs1016343, rs10993994 and
rs16901979, respectively). The primer concentration for
rs5945619 was therefore decreased (Table 2).
Regarding the quintuplex pyro-signals before primer
adjustment, the average relative signal contribution of
rs4430796 (5.8%) and of rs10896449 (10.1%) were smaller
than rs6983267 (21.6%), while the average relative sig-
nal contributions of the two remaining SNPs were sig-
nificantly higher (35.6% for rs1859962 and 25.9% for
rs4242382). The primer concentration was therefore
increased for rs4430796 and rs10896449 and decreased
for rs1859962 and rs4242382 (Table 2).
Multiplex PCR andmultiplex pyrosequencing
Multiplex pyrosequencing was carried out on PCR prod-
ucts produced with adjusted PCR primer concentrations.
Gel electrophoresis of the quadruplex and quintuplex PCR
products is displayed in Fig. 2. Given the similar sizes of
the amplification products for the five analyzed SNPs in
the quintuplex PCR (rs6983267 : 295 bp, rs1859962 : 177
bp, rs10896449 : 274 bp, rs4430796 : 254 bp, rs4242382 :
250 bp), only 3 bands were present on the gel (samples
1-4). Regarding the quadruplex PCR (samples 5-8), the
picture of the electrophoresis gel shows 4 bands, cor-
responding to the amplification products for rs1016343
(279 bp), rs10993994 (250 bp), rs5945619 (234 bp) and
rs16901979 (191 bp), respectively.
All pyro-signals were analyzed using AdvISER-MH-
PYRO. For the quadruplex assay, the average relative
signal contribution of rs5945619 (17.2%) decreased and
approached the respective contribution of the other three
SNPs (18.1% for rs1016343, 16.9% for rs10993994, and
47.7% for rs16901979) (Table 4).
For the quintuplex assay, the average contribution
of rs4430796 (12.6%) and rs10896449 (19.3%) were
increased while the contribution of rs1859962 (16.6%)
was significantly decreased and approached the contribu-
tions of the remaining SNPs (24.4% for rs6983267 and
26.7% for rs4242382) (Table 5).
Although the contribution of all SNPs was not perfectly
balanced in both assays, all genotypes (n=90) generated
with the quadruplex (Table 4) and quintuplex (Table 5)
assays were perfectly (100%) concordant with uniplex
pyrosequencing results (Table 3). Moreover, all results
were associated with a high confidence index (r>0.997).
Accordingly, PCR primer concentrations were not further
adjusted.
Table 3 Individual genotype (n=10) for selected SNPs (n=9)
Patient rs1016343 rs10993994 rs16901979 rs5945619 rs10896449 rs1859962 rs4242382 rs4430796 rs6983267
1 C/C T/T C/C T G/G G/G G/G A/A G/T
2 C/C C/C C/C T A/G T/T G/G A/A G/T
3 C/C C/C C/C C A/G T/T G/G G/G G/T
4 C/C C/C C/C T A/G T/G G/G A/A G/G
5 C/C C/T C/C T G/G T/T G/G G/A T/T
6 T/T C/T C/C T A/G T/T G/G G/A T/T
7 C/C C/T C/C T A/G T/G G/G G/A G/G
8 C/T C/T A/A T A/A T/T G/G A/A G/T
9 C/C C/C C/C C G/G T/T A/G G/A T/T
10 C/C C/C C/C T A/G G/G G/G G/A G/T
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Fig. 2 Picture of electrophoresis gel of amplification products obtained with 3 DNA samples and 1 negative control, for the quintuplex (samples 1-4)
and quadruplex (samples 5-8) PCR, respectively
Illustration of AdvISER-MH-PYRO
Figure 3 illustrates the results obtained with AdvISER-
MH-PYRO when applied on quadruplex (left) and quin-
tuplex (right) pyro-signals generated for the first patient.
Both signals are correctly converted into four and five
genotypes, respectively.
In both cases, the high confidence index (R=0.998 for
quadruplex, R>0.999 for quintuplex) traduces the quasi
perfect correlation between the observed multiplex pyro-
signal (vertical black lines) and the sparse regression
model (colored boxes). As illustrated in Fig. 3, colored
boxes, which result from software analysis, fit quasi per-
fectly the vertical black lines representing the global mul-
tiplex pyro-signal produced by the pyrosequencer.
Interoperability of the dictionary
Irrespective of the equipment used to carry out the
pyrosequencing analysis, all genotypes generated with the
quadruplex and quintuplex assays were perfectly (100%)
concordant with gold standard results as reported in
Table 3.
Impact on analytical reagent costs, production of waste
material and TAT
TAT of uniplex and multiplex methods were also com-
pared. Considering that each PCR and pyrosequencing
plates includes 96 wells and that negative controls are
required, the comparison was performed on a hypotheti-
cal set of 90 patients. Whereas buffy coat, DNA extraction
and quantification (30, 30 and 20 min, respectively) were
identical for both methods, the estimated TAT of PCR
(i.e, 165 min) and pyrosequencing (i.e., 60-70 min) car-
ried out in 9 uniplex versus 2 multiplex analyses, was 2025
([165 + 60]*9 ) versus 470 ([165 +70]*2) min, respectively.
Analytical costs for analyzing 9 SNPs with the clas-
sical uniplex and multiplex pyrosequencing approach
were ∼ 229 and ∼ 64 US$/patient, respectively
(Table 6).
Using the multiplex approach resulted in an important
reduction of waste material produced (∼ 75% less than
the uniplex method), in terms of quantities of PCR and
pyrosequencing plates, pipette tips and reagent bottles
(Table 7).
Conclusions
The present proof-of-concept study aimed to demon-
strate the feasibility of SNP multiplex pyrosequencing
with the newAdvISER-MH-PYRO algorithm and to assess
its impact in terms of cost, TAT and waste material.
In this respect, a combination of two multiplex pyrose-
quencing assays was developed to test in two runs a
set of nine prostate cancer-related SNPs. Appropriate
nucleotide dispensation orders were selected with the
SENATOR function which considers all UNS expected
to be found within each genomic region of interest in
order to produce uncorrelated uniplex pyrosequencing
signals. Multiplex pyro-signals were then analyzed with
a new algorithm developed by our team (AdvISER-MH-
PYRO). All quadruplex and quintuplex pyro-signals were
converted into 4 and 5 genotypes, respectively.
To the best of our knowledge, it is the first time that
quadruplex and quintuplex pyro-signals from amplicons
generated by amultiplex PCR amplification in a single well
are translated into their respective single counterpart and
that bi-allelic variants of each target gene are simultane-
ously identified and assigned. All multiplex results were
perfectly (100%) concordant with uniplex results. The lat-
ter were taken as gold-standard in this study, considering
that uniplex pyrosequencing distinguishes reliably the
specific pattern associated with each of the various geno-
types, providing therefore accurate typing results [13], as














Table 4 Quadruplex (n=4) pyro-signals (n=10): results of AdvISER-MH-PYRO after adjustement of primer concentrations
Patient rs1016343 rs10993994 rs16901979 rs5945619 Ra
Genotype Contributiona (%) Genotype Contributiona (%) Genotype Contributiona (%) Genototype Contributiona (%)
1 C/C 4.36 (18.6) T/T 2.87 (12.2) C/C 11.35 (48.4) T 4.85 (20.7) 0.999
2 C/C 5.52 (20.5) C/C 7.05 (26.2) C/C 10.71 (39.8) T 3.66 (13.6) 0.998
3 C/C 4.58 (19.6) C/C 3.66 (15.6) C/C 11.09 (47.4) C 4.09 (17.5) 0.999
4 C/C 2.85 (16.4) C/C 2.23 (12.8) C/C 9.78 (56.1) T 2.57 (14.7) 0.999
5 C/C 4.97 (18.8) C/T 5.34 (20.2) C/C 10.63 (40.3) T 5.44 (20.6) 0.999
6 T/T 3.92 (16.3) C/T 4.93 (20.5) C/C 10.2 (42.5) T 4.95 (20.6) >0.999
7 C/C 3.98 (17.9) C/T 3.87 (17.4) C/C 10.23 (45.9) T 4.2 (18.9) 0.997
8 C/T 4.87 (18.3) C/T 5.19 (19.5) A/A 12.41 (46.6) T 4.18 (15.7) 0.999
9 C/C 3.05 (18.4) C/C 1.82 (11.0) C/C 9.18 (55.3) C 2.56 (15.4) 0.999
10 C/C 2.72 (16.2) C/C 2.35 (14.0) C/C 9.29 (55.2) T 2.46 (14.6) >0.999
Average 18.1 16.9 47.7 17.2
aFor each patient, the genotype and its absolute and relative contributions to the global signal are computed by AdvISER-MH-PYRO for each SNP, R: confidence index traducing the correlation between the observed multiplex














Table 5 Quintuplex (n=5) pyro-signals (n=10): results of AdvISER-MH-PYRO after adjustement of primer concentrations
Patient rs10896449 rs1859962 rs4242382 rs4430796 rs6983267 R
Genotype Contriutiona (%) Genotype Contributiona (%) Genotype Contributiona (%) Genotype Contributiona (%) Genotype Contributiona (%)
1 G/G 5.51 (19.4) G/G 8.79 (30.9) G/G 5.75 (20.2) A/A 3.24 (11.4) G/T 5.13 (18.1) 0.998
2 A/G 5.82 (23.2) T/T 4.05 (16.1) G/G 6.91 (27.5) A/A 2.33 (9.3) G/T 6.00 (23.9) 0.998
3 A/G 5.67 (21.0) T/T 3.96 (14.7) G/G 7.63 (28.3) G/G 3.31 (12.3) G/T 6.40 (23.7) 0.999
4 A/G 5.07 (20.6) T/G 3.50 (14.2) G/G 6.44 (26.1) A/A 3.30 (13.4) G/G 6.36 (25.8) 0.996
5 G/G 5.55 (19.3) T/T 3.52 (12.2) G/G 7.74 (26.9) G/A 3.14 (10.9) T/T 8.86 (30.8) 0.999
6 A/G 7.28 (22.4) T/T 4.91 (15.1) G/G 7.47 (23.0) G/A 5.21 (16.0) T/T 7.64 (23.5) 0.998
7 A/G 6.35 (21.1) T/G 4.28 (14.2) G/G 8.22 (27.3) G/A 4.28 (14.2) G/G 7.00 (23.2) 0.996
8 A/A 0.94 (10.7) T/T 1.47 (16.7) G/G 2.82 (32.1) A/A 1.57 (17.9) G/T 1.99 (22.6) 0.998
9 G/G 4.73 (18.6) T/T 4.43 (17.4) A/G 6.80 (26.8) G/A 2.17 (8.5) T/T 7.27 (28.6) 0.997
10 A/G 4.23 (14.5) G/G 3.07 (14.5) G/G 6.15 (29.1) G/A 2.50 (11.8) G/T 5.16 (24.4) 0.999
Average (19.3) (16.6) (26.7) (12.6) (24.4)
aFor each patient, the genotype and its absolute and relative contributions to the global signal are computed by AdvISER-MH-PYRO for each SNP, R: confidence index traducing the correlation between the observed multiplex
pyro-signal and the sparse regression model constructed by AdvISER-MH-PYRO
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Fig. 3 Example of a quadruplex (left) and quintuplex (right) pyro-signal identification with AdvISER-MH-PYRO.The multiplex pyro-signal generated
by the pyrosequencing machine is displayed before (top) and after (bottom) the analysis. In both cases, it is represented by vertical black lines. After
analysis, the contribution of each atom (i.e., each uniplex pyro-signal within the dictionary) is represented by colored boxes stacked on top of the
other
versus Sanger sequencing [14, 15]. The analytical reagent
costs, waste production and TAT of conventional uni-
plex and new multiplex pyrosequencing assays were com-
pared. The newmultiplex approach allowed to lower costs
and waste material production by ∼ 70% and ∼ 75%,
respectively. In an era where research laboratories strive
to be more environmentally-friendly, this new multiplex
method could therefore contribute to minimize waste
disposal and footprint. The comparison of TAT was also
clearly in favor of themultiplex approach. TATwas indeed
reduced by ∼ 75%, without any compromise on results
Table 6 Analytical reagent costs (US $)
Uniplex (n=9) Quadruplex (n=1)
+Quintuplex (n=1)
DNA extraction ∼ 16.5 ∼ 16.5
PCR ∼ 71.0 ∼ 16.0
Pyrosequencing ∼ 141.5 ∼ 31.5
TOTAL ∼ 229.0 ∼ 64.0
quality and reliability and despite a multiplex pyrose-
quencing run being 10 min longer due to a higher number
of dispensed nucleotides.
While uniplex SNP pyrosequencing does not com-
pete with with faster and more cost-effective methods
(TaqMan [16] or Sequenom [17]), current improvements
enabling multiplexing makes it a suitable alternative to
the latter methods in terms of TAT, cost and waste pro-
duction. Although not assessed in this study, in-del could
Table 7 Waste material produced for a full 96-well plate
Uniplex (n=9) Quadruplex (n=1)
+ Quintuplex (n=1)
PCR plates (n) 9 2
Pipette tips - PCR (n) 936 222
Pyrosequencing plates (n) 9 2
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also be genotyped in a multiplex experiment with the
AdvISER-MH-PYRO algorithm.
Considering that the AdvISER-MH-PYRO software and
both dictionaries are available in the corresponding pack-
age (www.uclouvain.be/ctma.html), and that PCR condi-
tions have already been optimized, these new assays can
also easily be implemented in other laboratories now. As
evidenced by this study, multiplexing has proved to be
particularly relevant when developing new rapid, robust,
reliable, cleaner and cost-effective SNP genotyping assays.
While the added clinical value of MGRS based on 9 PCa
risk-associated SNPs proved indeed not bring a major
benefit as previously discussed [5], it was technologically
interesting to repeat this SNP analysis using the multiplex
pyrosequencing method, especially because this method
is widely applicable to a range of other clinical and/or
research applications, all relying also on MGRS compu-
tation, and therefore requiring multi-SNP genotyping for
each patient. Such applications are currently developed
in a wide range of diseases, including coronary heart
disease [18], liver diseases [19] and acute lymphoblastic
leukemia [20]. For these, the methodology reported in this
paper is implementable subject to optimization of primers
concentration, to building a standardized uniplex pyro-
signals-based dictionary and to carrying outmultiplex sig-
nal analysis with the newly available AdvISER-MH-PYRO
function.
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